Quelle place pour la chirurgie bariatrique dans le traitement de la stéatohépatite non alcoolique ?

Line Carolle Ntandjawandji (1) , Gregory Baud (1, 2) , Guillaume Lassailly (3, 1)

1 Hôpital Claude Huriez [Lille]
2 EGID - Institut Européen de Génomique du Diabète - European Genomic Institute for Diabetes - FR 3508
3 LIRIC - Lille Inflammation Research International Center - U 995

Bariatric surgery is indicated for patients with BMI≥35kg/m2 and associated steatohepatitis. Bariatric surgery induces NASH disappearance for nearly 80% of patients after 1 year of follow up. Bariatric surgery is associated with low morbidity and mortality if patients are well selected. Bariatric surgery is contraindicated in patients with cirrhosis. Long-term data are needed to determine the risk of recurrence of NASH. The extension of indications for bariatric surgery to patients with BMI less than 35kg/m2 will depend on the results of randomized trials.

Domaines: Sciences du Vivant [q-bio]

Line Carolle Ntandjawandji, Gregory Baud, Guillaume Lassailly. Quelle place pour la chirurgie bariatrique dans le traitement de la stéatohépatite non alcoolique ?. La Presse Médicale, 2019, 48, pp.1502 - 1506. ⟨10.1016/j.lpm.2019.09.016⟩. ⟨hal-03488814⟩